Belapectin Explained

Drug Name:	Belapectin
Legal Status:	Investigational
Cas Number:	1980787-47-0
Cas Number2:	1604015-18-0
Unii:	K7ODU55HT6
Iupac Name:	α-D-Galacturono-α-D-galacto-β-D-galacto-6-deoxy-α-L- manno-α-L-arabinan, (1→2),(1→3),(1→4)-, methyl ester

Belapectin (also known as GR-MD-02) is a galectin-3 inhibitor developed by Galectin Therapeutics that is in clinical trials for the treatment of non-alcoholic steatohepatitis.^{[1] [2] [3] [4]}

Notes and References

1. Web site: Mireku . Akosua . NASH drugs race to cross the finish line . Pharmaceutical Technology . 21 October 2023 . 26 June 2023.
2. Al Attar . Atef . Antaramian . Ani . Noureddin . Mazen . Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis . Expert Review of Clinical Pharmacology . 3 April 2021 . 14 . 4 . 457–464 . 10.1080/17512433.2021.1894127.
3. Slack . R.J. . Mills . R. . Mackinnon . A.C. . The therapeutic potential of galectin-3 inhibition in fibrotic disease . The International Journal of Biochemistry & Cell Biology . January 2021 . 130 . 105881 . 10.1016/j.biocel.2020.105881. free .
4. Tapper . Elliot B. . Ufere . Nneka N. . Huang . Daniel Q. . Loomba . Rohit . Review article: current and emerging therapies for the management of cirrhosis and its complications . Alimentary Pharmacology & Therapeutics . May 2022 . 55 . 9 . 1099–1115 . 10.1111/apt.16831 . en . 0269-2813.